Ketamine therapy has recently faced increased scrutiny due to high-profile incidents like Matthew Perry’s death and FDA comments regarding home use of compounded ketamine. This raises important questions about ketamine’s role within the psychedelic therapeutic community.
The Psychedelic Framework
Over the past decade, psychedelic research has expanded dramatically, examining compounds including psilocybin, 5-MeO-DMT, LSD, and MDMA. Despite their chemical differences, these treatments share a common therapeutic approach called the psychedelic framework.
This model consists of three essential components:
- Container — The foundation of safety, rapport, and trust between practitioner and patient
- Catalyst — An agent that alters psychological information flow, which could range from ketamine to breathwork techniques
- Carrier — Supportive elements like music, eye shades, or shared belief systems that direct the experience inward
Clinical Experience and Perspective
Dr. Scott Shannon brings extensive experience, having supervised over 7,000 ketamine sessions across eight years while serving as a Principal Investigator on studies involving MDMA, LSD, and group ketamine protocols. He also monitors underground practices and actively engages with psilocybin work through his Colorado clinic.
Key insights from this experience include:
- Different agents work differently for different individuals
- Each agent has distinct strengths and limitations
- Any agent can be misused harmfully
- Integration following the experience matters more than the journey itself
Ketamine’s Therapeutic Value
Ketamine can be every bit as powerful and transformational as MDMA or psilocybin, though it lacks the durability of those agents. Its significance lies in its legal status and widespread adoption by thousands of psychedelically-oriented practitioners nationwide.
Dr. Shannon positions ketamine as a transitional molecule helping psychiatry move beyond the outdated “chemical imbalance” model toward the integrative psychiatry model and a more dynamic understanding of consciousness.
The Core Message
The psychedelic community should avoid dismissing certain agents while elevating others. Instead, the focus should remain on protecting the therapeutic framework itself. The methodology matters more than the specific compound used.
Current Challenges in Colorado
Following the passage of Proposition 122, Colorado faces a gold rush of excess and hyperbole. Law enforcement and regulators are still developing appropriate responses. Problematic outcomes will likely result from compromised or absent therapeutic containers rather than the substances themselves.
Dr. Shannon emphasizes that the community must unite around the psychedelic framework rather than focusing exclusively on particular compounds. This unified approach protects against the inevitable misuses that emerge as these therapies gain wider availability.
About Dr. Scott Shannon
Dr. Shannon is a founding member of the Psychedelic Research and Training Institute (PRATI) and played a pivotal role in establishing the Board of Psychedelic Medicine and Therapies in 2021, serving as its founding CEO. He is recognized for advancing psychedelic medicine access through international lectures and advocacy.